1Stewart L, Redinbo MR, Qiu X, et al. A model for the mechanism of human topoisomerase Ⅰ [J]. Science, 1998, 279(5356): 1534 - 1541.
2Redinbo MR, Champoux JJ, Hol WG. Novel insights into catalytic mechanism from a crystal structure of human topoisomerase Ⅰ in complex with DNA[J]. Biochemistry,2000,39(23) :6832 - 6840.
3Leteurtre F, Fujimori A, Tanizawa A, et al. Saintopin, a dual inhibitor of DNA topoisomerases Ⅰ and Ⅱ, as a probe for drug-enzyme interactions[J]. J Biol Chem, 1994, 269(46):28702- 28707.
4Janin YL, Croisy A, Riou JF, et al. Synthesis and evaluation of new 6-amino-substituted benzo[c] phenanthridine derivatives[J]. J Med Chem, 1993,36(23) :3686 - 3692.
5Von-Hoff DD, Burris HA, Eckardt J, et al. Preclinical and phase Ⅰ trials of topoisomerase Ⅰ inhibitors [J]. Cancer Chemother Pharmacol,1994, 34(Suppl):S41- S45.
6Utsugi T, Aoyagi K, Asao T, et al. Antitumor activity of a novel quinoline derivative, TAS-103, with inhibitory effects on topoisomerases Ⅰ tand Ⅱ [J]. Jpn J Cancer Res, 1997,88(10) :992 - 1002.
7Bridewell DJ, Finlay GJ, Baguley BC. Differential actions of aclarubicin and doxorubicin: the role of topoisomerase Ⅰ[J]. Oncol Res, 1997, 9(10) :535 - 542.
8Kim JS, Sun Q, Gatto B, et al. Structure-activity relationships of benzimidazoles and related heterocycles as topoisomerase Ⅰ poisons[J]. Bioorg Med Chem, 1996, 4(4) :621 - 630.
9Kim JS, Sun Q, Yu C, et al. Quantitative structure-activity relationships on 5-substituted terbenzimidazoles as topoisomerase Ⅰ poisons and antitumor agents [J]. Bioorg Med Chem, 1998,6(2): 163 - 172.
10Fujii N, Yamashita Y, Saitoh Y, et al. Induction of mammalian DNA topoisomerase Ⅰ-mediated DNA cleavage and DNA winding by bulgarein [J]. J Biol Chem, 1993, 268(18): 13160- 13165.
